Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

Roberto Latagliata, MD, Ida Carmosino, Federico Vozella, Paola Volpicelli, MD, Giuseppina Loglisci, Michelina Santopietro, Adriano Salaroli, MD, Angela Romano, Chiara Montagna, Amanda Roberto, Alessandra Serrao, Daniela Diverio, PhD, Mauro Nanni, PhD, Marco Mancini, Agostino Tafuri, Massimo Breccia, Giuliana Alimena, MD

Blood (2013) 122 (21): 4002.

https://doi.org/10.1182/blood.V122.21.4002.4002

Published: 2013

Journal Articles

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Hagop M. Kantarjian, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Kapil N. Bhalla, MD, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, PhD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Giovanni Martinelli, MD, Dong-Wook Kim, MD, PhD, Yaping Shou, MD, PhD, Neil J. Gallagher, MD, PhD, Jim Wang, PhD, Jorge Cortes-Franco, MD, Michele Baccarani, MD, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 1129.

https://doi.org/10.1182/blood.V114.22.1129.1129

Published: 2009

Journal Articles

Liver Patology in Patients with Hematological Malignancies.

Natalia P. Domnikova, MD, Natalia V. Teterina, MD, PhD

Blood (2006) 108 (11): 4432.

https://doi.org/10.1182/blood.V108.11.4432.4432

Published: 2006

Journal Articles

Trypsin Mediated Activation of Thrombin Activatable Fibrinolytic Inhibitor (Carboxypeptidase U): Potential Clinical Implications.

Michelle Kujawski, BS, Josephine Cunanan, MD, Debra A. Hoppensteadt, PhD, Rodger L. Bick, MD/PhD, Jawed Fareed, PhD

Blood (2006) 108 (11): 4016.

https://doi.org/10.1182/blood.V108.11.4016.4016

Published: 2006

Journal Articles

Isolated, Idiopathic Splenic Vein Thrombosis, Presenting with Massive Lower GI Bleeding.

Aref Agheli, MD, Alka Arora, MD, Maged Khalil, MD, Seema Naik, MD, Theresa Dumlao, MD, William Steier, MD, Madhumati Kalavar, MD

Blood (2005) 106 (11): 4131.

https://doi.org/10.1182/blood.V106.11.4131.4131

Published: 2005

NARROW

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Liver Patology in Patients with Hematological Malignancies.

Trypsin Mediated Activation of Thrombin Activatable Fibrinolytic Inhibitor (Carboxypeptidase U): Potential Clinical Implications.

Isolated, Idiopathic Splenic Vein Thrombosis, Presenting with Massive Lower GI Bleeding.

Email alerts

ASH Publications

American Society of Hematology

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Liver Patology in Patients with Hematological Malignancies.

Trypsin Mediated Activation of Thrombin Activatable Fibrinolytic Inhibitor (Carboxypeptidase U): Potential Clinical Implications.

Isolated, Idiopathic Splenic Vein Thrombosis, Presenting with Massive Lower GI Bleeding.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only